EHD2 and Autoimmunity: EHD2-sc-mTNFR2, the agonist used in this study, was used successfully to treat EAE symptoms [44], with its positive effects attributed in part to the promotion of peripheral Treg expansion and subsequent suppression of autoimmunity.